臨床泌尿器科60巻12号

2006年11月発行

特集 ここが知りたい―癌薬物療法

腎細胞癌の薬物療法―分子標的薬について

著者： 濱口益光¹ 江藤正俊¹

所属機関： ¹九州大学大学院医学研究院泌尿器科学分野

ページ範囲：P.869 - P.874

文献概要

　転移性腎細胞癌は，現在最も治療抵抗性な悪性腫瘍の一つである。しかしながら腎細胞癌を構築する分子レベルでの理解がより良い治療法への発展へとつながっていき，そしてそれは現在，臨床応用へと進んでいる。現在のところ，VEGFR（血管内皮増殖因子受容体）の経路が最も有望なターゲットであるが，それだけではなく他の受容体〔platelet-derived growth factor receptor（PDGFR），FMS-like tyrosine kinase 3（FLT3），KIT，Raf kinaseなど〕も阻害する2つの薬剤，BAY 43-9006とSU 11248は，進行性腎細胞癌に対して最近FDAの承認を得ている。現在進行中の臨床試験のさらなる経過観察は必要であるが，これら分子標的薬が今後の腎細胞癌の治療戦略の鍵を握っている。

参考文献

1）Bukowski RM：Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19：148-154, 2001

2）Eto M and Naito S：Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol 11：209-213, 2006

3）Dvorack HF：Vascular permeability factor/vascular endothelial growth factor：a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 21：4368-4380, 2002

4）Ichikura H, Eto M, Ueno H, et al：In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor. Oncol Rep 15：1333-1337, 2006

5）Kibel A, Iliopous O, DeCaprio JA, et al：Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269：1444-1446, 1995

6）Maxwell PH, Wiesener MS, Chang GW, et al：The tumour suppressor protein VHL targets hypoxia-nducible factors for oxygen-dependent proteolysis. Nature 399：271-275, 1999

7）Cockman ME, Masson N, Mole DR, et al：Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275：25733-25741, 2000

8）Iliopoulos O, Levy AP, Jiang C, et al：Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93：10595-10599, 1996

9）Gnarra JR, Zhou S, Merrill MJ, et al：Posttranscriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93：10589-10594, 1996

10）Kourembanas S Hannan RL and Faller DV：Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 86：670-674, 1990

11）Yang JC, Haworth L, Sherry RM, et al：A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349：427-434, 2003

12）Motzer RJ, Michaelson MD, Redman BG, et al：Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24：16-24, 2006

13）Motzer RJ, Rini BI, Michaelson MD, et al：Sunitinib malate（SU11248）shows antitumor activity in patients with metastatic renal cell carcinoma：updated results from phaseⅡ trials. Eur J Cancer Suppl 3：227（abstract 797）, 2005

14）Motzer RJ, Hutson TE, Tomczak P, et al：Phase Ⅲ randomized trial of sunitinib malate（SU11248）versus interferon-alfa（IFN-α）as first-line systemic therapy for patients with metastatic renal cell carcinoma（mRCC）. ASCO Proc（abstract LBA3）, 2006

15）Wilhelm SM, Carter C, Tang L, et al：BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64：7099-7109, 2004

16）Escudier B, Szczylik C, Eisen T, et al：Randomized Phase Ⅲ trial of the Raf kinase and VEGFR inhibitor sorafenib（BAY 43-9006）in patients with advanced renal cell carcinoma（RCC）. ASCO Proc（abstract 4510）, 2005

17）Eisen T, Bukowski RM, Staehler M, et al：Randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma（RCC）：Impact of crossover on survival. ASCO Proc（abstract 4524）, 2006

18）Dhanda R, Gondek K, Song J, et al：A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. ASCO Proc（abstract 4534）, 2006

19）Rini B, Rixe O, Bukowski R, et al：AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer（RCC）. ASCO Proc（abstract 4509）, 2005

20）Gibbons JJ, Discafani C and Peterson R：The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc Am Assoc Cancer Res 40：301（abstract 1000）, 1999

21）Atkins MB, Hidalgo M, Stadler WM, et al：Randomized phaseⅡ study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22：909-918, 2004

22）Hudes G, Carducci M, Tomczak P, et al：A phase 3, randomized, 3-arm study of temsirolimus（TEMSR）or interferon-alpha（IFN）or the combination of TEMSR＋IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma（adv RCC）. ASCO Proc（abstract LBA4）, 2006

23）Hainsworth JD, Sosman JA, Spigel DR, et al：Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol Nov 1：23（31）：7889-7896, Epub 2005

24）Bukowski RM, Kabbinavar F, Figlin RA, et al：Bevacizumab with or without erlotinib in metastatic renal cell carcinoma（RCC）. ASCO Proc（abstract 4523）, 2006